346 related articles for article (PubMed ID: 19889066)
1. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE.
Aaronson D; Cowan J; Carroll P; Konety B
BJU Int; 2010 Apr; 105(7):951-5. PubMed ID: 19889066
[TBL] [Abstract][Full Text] [Related]
2. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
3. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
D'Amico AV; Loffredo M; Renshaw AA; Loffredo B; Chen MH
J Clin Oncol; 2006 Sep; 24(25):4190-5. PubMed ID: 16943536
[TBL] [Abstract][Full Text] [Related]
4. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
5. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
6. Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy.
Chen RC; Sadetsky N; Chen MH; Carroll PR; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):36-9. PubMed ID: 19233568
[TBL] [Abstract][Full Text] [Related]
7. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
8. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
9. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
Palma D; Tyldesley S; Pickles T;
Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
[TBL] [Abstract][Full Text] [Related]
13. Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1439-44. PubMed ID: 19540066
[TBL] [Abstract][Full Text] [Related]
14. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
15. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
[TBL] [Abstract][Full Text] [Related]
16. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
[TBL] [Abstract][Full Text] [Related]
17. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
Galalae RM; Martinez A; Mate T; Mitchell C; Edmundson G; Nuernberg N; Eulau S; Gustafson G; Gribble M; Kovács G
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1048-55. PubMed ID: 15001244
[TBL] [Abstract][Full Text] [Related]
19. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]